227 related articles for article (PubMed ID: 16537666)
41. Predictors of mortality in alpha1-antitrypsin deficiency.
Dawkins PA; Dowson LJ; Guest PJ; Stockley RA
Thorax; 2003 Dec; 58(12):1020-6. PubMed ID: 14645964
[TBL] [Abstract][Full Text] [Related]
42. Volume correction in computed tomography densitometry for follow-up studies on pulmonary emphysema.
Stoel BC; Putter H; Bakker ME; Dirksen A; Stockley RA; Piitulainen E; Russi EW; Parr D; Shaker SB; Reiber JH; Stolk J
Proc Am Thorac Soc; 2008 Dec; 5(9):919-24. PubMed ID: 19056717
[TBL] [Abstract][Full Text] [Related]
43. Long-range correlations of serial FEV1 measurements in emphysematous patients and normal subjects.
Dirksen A; Holstein-Rathlou NH; Madsen F; Skovgaard LT; Ulrik CS; Heckscher T; Kok-Jensen A
J Appl Physiol (1985); 1998 Jul; 85(1):259-65. PubMed ID: 9655784
[TBL] [Abstract][Full Text] [Related]
44. Progression of emphysema evaluated by MRI using hyperpolarized (3)He (HP (3)He) measurements in patients with alpha-1-antitrypsin (A1AT) deficiency compared with CT and lung function tests.
Stavngaard T; Søgaard LV; Batz M; Schreiber LM; Dirksen A
Acta Radiol; 2009 Nov; 50(9):1019-26. PubMed ID: 19863412
[TBL] [Abstract][Full Text] [Related]
45. CT scan appearance, densitometry, and health status in protease inhibitor SZ alpha1-antitrypsin deficiency.
Holme J; Stockley RA
Chest; 2009 Nov; 136(5):1284-1290. PubMed ID: 19892672
[TBL] [Abstract][Full Text] [Related]
46. Alpha-1-antitrypsin replacement therapy: current status.
Abusriwil H; Stockley RA
Curr Opin Pulm Med; 2006 Mar; 12(2):125-31. PubMed ID: 16456382
[TBL] [Abstract][Full Text] [Related]
47. Decline in FEV1 in patients with PiZ alpha-1-antitrypsin deficiency: the Australian experience.
Burdon JG; Brenton S; Hocking V; Knight KR; Ayad M; Cook L; Janus ED
Respirology; 2002 Mar; 7(1):51-5. PubMed ID: 11896901
[TBL] [Abstract][Full Text] [Related]
48. Alpha1-antitrypsin deficiency: a position statement of the Canadian Thoracic Society.
Abboud RT; Ford GT; Chapman KR;
Can Respir J; 2001; 8(2):81-8. PubMed ID: 11320399
[TBL] [Abstract][Full Text] [Related]
49. Quantitative disease progression model of α-1 proteinase inhibitor therapy on computed tomography lung density in patients with α-1 antitrypsin deficiency.
Tortorici MA; Rogers JA; Vit O; Bexon M; Sandhaus RA; Burdon J; Chorostowska-Wynimko J; Thompson P; Stocks J; McElvaney NG; Chapman KR; Edelman JM
Br J Clin Pharmacol; 2017 Nov; 83(11):2386-2397. PubMed ID: 28662542
[TBL] [Abstract][Full Text] [Related]
50. Relations between cardiopulmonary exercise testing and quantitative high-resolution computed tomography associated in patients with alpha-1-antitrypsin deficiency.
Schwaiblmair M; Beinert T; Seemann M; Behr J; Reiser M; Vogelmeier C
Eur J Med Res; 1998 Nov; 3(11):527-32. PubMed ID: 9810033
[TBL] [Abstract][Full Text] [Related]
51. An unusual case of rapid radiological progression of bullous emphysema secondary to severe α1-antitrypsin deficiency.
Chew JR; Roy K; Babar J; Mahadeva R
BMJ Case Rep; 2015 May; 2015():. PubMed ID: 25953582
[No Abstract] [Full Text] [Related]
52. Relationship between loss in parenchymal elastic recoil pressure and maximal airway narrowing in subjects with alpha1-antitrypsin deficiency.
Cheung D; Schot R; Zwinderman AH; Zagers H; Dijkman JH; Sterk PJ
Am J Respir Crit Care Med; 1997 Jan; 155(1):135-40. PubMed ID: 9001302
[TBL] [Abstract][Full Text] [Related]
53. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group.
Seersholm N; Wencker M; Banik N; Viskum K; Dirksen A; Kok-Jensen A; Konietzko N
Eur Respir J; 1997 Oct; 10(10):2260-3. PubMed ID: 9387950
[TBL] [Abstract][Full Text] [Related]
54. Towards local progression estimation of pulmonary emphysema using CT.
Staring M; Bakker ME; Stolk J; Shamonin DP; Reiber JH; Stoel BC
Med Phys; 2014 Feb; 41(2):021905. PubMed ID: 24506626
[TBL] [Abstract][Full Text] [Related]
55. Clinical features and prognosis of life time non-smokers with severe alpha 1-antitrypsin deficiency.
Seersholm N; Kok-Jensen A
Thorax; 1998 Apr; 53(4):265-8. PubMed ID: 9741368
[TBL] [Abstract][Full Text] [Related]
56. The impact of smoke exposure on the clinical phenotype of alpha-1 antitrypsin deficiency in Ireland: exploiting a national registry to understand a rare disease.
O'Brien ME; Pennycooke K; Carroll TP; Shum J; Fee LT; O'Connor C; Logan PM; Reeves EP; McElvaney NG
COPD; 2015 May; 12 Suppl 1():2-9. PubMed ID: 25938284
[TBL] [Abstract][Full Text] [Related]
57. Mortality in alpha-1-antitrypsin deficiency in the United Kingdom.
Dawkins P; Wood A; Nightingale P; Stockley R
Respir Med; 2009 Oct; 103(10):1540-7. PubMed ID: 19443188
[TBL] [Abstract][Full Text] [Related]
58. Impact of emphysema and airway wall thickness on quality of life in smoking-related COPD.
Gietema HA; Edwards LD; Coxson HO; Bakke PS;
Respir Med; 2013 Aug; 107(8):1201-9. PubMed ID: 23711580
[TBL] [Abstract][Full Text] [Related]
59. Intermediate alpha 1-antitrypsin deficiency PiSZ: a risk factor for pulmonary emphysema?
Seersholm N; Kok-Jensen A
Respir Med; 1998 Feb; 92(2):241-5. PubMed ID: 9616519
[TBL] [Abstract][Full Text] [Related]
60. One- to four-year follow-up of endobronchial lung volume reduction in alpha-1-antitrypsin deficiency patients: a case series.
Hillerdal G; Mindus S
Respiration; 2014; 88(4):320-8. PubMed ID: 25227936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
